Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240288 | 1.00 | HTR1A (0.44) | HTR1ACYP19A1DRD2DRD1HTR1B | |
| SCHEMBL19829900 | 0.83 | MAP3K14 (0.45) | HTR1ADRD2HTR2AADRA1A | |
| SCHEMBL3412427 | 0.83 | NPC1 (0.43) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL3408454 | 0.83 | ADRA1D (0.38) | HTR1AHTR2CADRA1DADRA1AADRA1B | |
| SCHEMBL3581276 | 0.74 | ALDH1A1 (0.35) | DRD2HTR2AHTR2CADRA1AALDH1A1 | |
| SCHEMBL9787362 | 0.74 | CYP3A4 (0.40) | HTR1ACYP19A1DRD2DRD1HTR1B | |
| SCHEMBL21262962 | 0.74 | CYP19A1 (0.45) | HTR1ACYP19A1ADRA1DADRA1AADRA1B | |
| SCHEMBL20480264 | 0.74 | CYP19A1 (0.45) | HTR1ACYP19A1ADRA1DADRA1AADRA1B | |
| SCHEMBL9620283 | 0.74 | CYP3A4 (0.40) | HTR1ACYP19A1DRD2DRD1HTR1B | |
| SCHEMBL9787063 | 0.74 | CYP3A4 (0.40) | HTR1ACYP19A1DRD2DRD1HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8044047-B2 | 5-substituted benzoxazines | HOFFMAN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-7994324-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2328880-A2 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2328881-A1 | 5-SUBSTITUTED BENZOXAZINES | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2262773-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010026110-A2 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063042-A1 | 5-SUBSTITUTED BENZOXAZINES | HOFFMANN-LA ROCHE, INC. | 2010-03-11 | — | — | US | disclosed |
| WO-2010026112-A1 | 5-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109491-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | HTR1A 6/4885CYP19A1 1828/4885DRD2 22/4885 |
| US-20090227584-A1 | 2-AMINOQUINOLINE DERIVATIVES | HTR5A, HTR2C, HTR2B | HTR1A 8/4885CYP19A1 1966/4885DRD2 28/4885 |
| US-20100063042-A1 | 5-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | HTR1A 9/4885CYP19A1 742/4885DRD2 80/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | HTR1A 4/4885CYP19A1 955/4885DRD2 35/4885 |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | HTR1A 7/4885CYP19A1 793/4885DRD2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.